EANM指南:镭-223治疗转移性去势抵抗性前列腺癌的放射性核素治疗
EANM发布镭-223治疗转移性去势抵抗性前列腺癌(CRPC)指南,适用于有症状骨转移且无已知内脏转移的患者。镭-223是首个在此适应症中提供生存获益的靶向α治疗,指南旨在帮助核医学专家评估候选患者、规划执行治疗、理解评价治疗后果并改善治疗及随访期间的患者管理。
要点
- 镭-223适用于有症状骨转移且无已知内脏转移的去势抵抗性前列腺癌(CRPC)患者。
- 镭-223是首个在此适应症中显示总生存和至首次症状性骨骼相关事件时间均获益的靶向α治疗。
- 镭-223选择性聚集于骨高转换区域,与羟基磷灰石形成复合物,α射线产生姑息性抗肿瘤效应。
核心结论
- 镭-223是首个在此适应症中提供总生存和至首次症状性骨骼相关事件时间显著生存获益的靶向α治疗。
- 指南旨在帮助核医学专家评估可能适合镭-223治疗的患者、规划执行治疗、理解评价治疗后果并改善治疗及随访期间的患者管理。
研究设计与样本
- 欧洲核医学协会(EANM)制定的指南,目的为协助核医学专家评估镭-223治疗候选患者、规划执行治疗、理解评价治疗后果并改善治疗及随访期间的患者管理。
主要发现
- 镭-223是首个在此适应症中提供新治疗选择的靶向α治疗,具有总生存和至首次症状性骨骼相关事件时间显著生存获益的证据。
- 骨骼是晚期前列腺癌患者最常见的转移部位,骨转移是临床显著的发病和死亡原因,常导致骨痛、病理性骨折或脊髓压迫而需要治疗。
- 镭-223通过与骨无机基质羟基磷灰石形成复合物而选择性聚集于骨,特别是高骨转换区域;放射性衰变产生的α射线对骨转移产生姑息性抗肿瘤效应。
关键数值与推荐
- 镭-223适用于有症状骨转移且无已知内脏转移的去势抵抗性前列腺癌(CRPC)患者的治疗。
临床怎么用
- 指南旨在协助核医学专家评估可能适合镭-223治疗的患者、规划并执行该治疗、理解并评价其后果,以及改善治疗和随访期间的患者管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radium Ra-223 dichloride (radium-223, Xofigo®) is a targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. Radium-223 is the first targeted alpha therapy in this indication providing a new treatment option, with evidence of a significant survival benefit, both in overall survival and in the time to the first symptomatic skeletal-related event. The skeleton is the most common metastatic site in patients with advanced prostate cancer. Bone metastases are a clinically significant cause of morbidity and mortality, often resulting in bone pain, pathologic fracture, or spinal cord compression necessitating treatment. Radium-223 is selectively accumulated in the bone, specifically in areas of high bone turnover, by forming complexes with the mineral hydroxyapatite (the inorganic matrix of the bone). The alpha radiation generated during the radioactive decay of radium-223 produces a palliative anti-tumour effect on the bone metastases. The purpose of this guideline is to assist nuclear medicine specialists in evaluating patients who might be candidates for treatment using radium-223, planning and performing this treatment, understanding and evaluating its consequences, and improving patient management during therapy and follow-up.
引用
- Poeppel TD, Handkiewicz-Junak D, Andreeff M, et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 29234845. doi:10.1007/s00259-017-3900-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。